Skip to main content
SpringerLink
Log in

Angiogenesis and the ET-1/ETA Receptor System: Immunohistochemical Expression Analysis in Bone Metastases from Patients with Different Primary Tumors

  • Published:
Angiogenesis Aims and scope Submit manuscript

Abstract

Angiogenesis is necessary for the growth of primary tumors and the formation of metastases. It is well known that vascular endothelial growth factor (VEGF) and its receptors play a major role in this process. To date, the formation of bone metastases has been poorly understood. Tumor cells must interact with the microenvironment of the bone and new blood vessels must spread. The ET/ETA(endothelin) receptor system seems to play an important role in this process. Specimens from metastatic bone lesions and non-malignant bone tissue were analyzed by histological and immunohistochemical staining. Sections were stained with antibodies against CD31, Flt-1, KDR, endothelin-1 (ET-1) and endothelin receptor A (ETA). Our studies show that there is an increased microvessel density (MVD) in metastatic bone lesions from different primary tumors in contrast to normal bone tissue. In nearly all tumor formations of the bone, ET-1 and its receptor ETA was found by immunohistochemistry. We also performed immunohistochemical staining for the VEGF-receptors Flt-1 and KDR. In conclusion, there is an increased vessel density in metastatic bone lesions in contrast to normal bone tissue. The ET/ETA system can be detected in nearly all bone specimens and is upregulated in metastatic bone lesions in contrast to healthy bone tissue.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971; 285: 1182–6.

    Article  PubMed  CAS  Google Scholar 

  2. Folkman J. Angiogenesis-dependent diseases. Semin Oncol 2001; 28: 536–42.

    Article  PubMed  CAS  Google Scholar 

  3. Folkman J. Anti-angiogenesis: New concept for therapy of solid tumors. Ann Surg 1972; 175: 409–16.

    PubMed  CAS  Google Scholar 

  4. Medinger M, Drevs J. Anti-Angiogenese gegen Krebs: VEGF-Inhibitoren in der klinischen Prüfung. [Anti-angiogenesis against cancer: VEGF inhibitors in clinical trials.] Dtsch Apoth Ztg 2003; 143: 52–62.

    Google Scholar 

  5. Drevs J, Medinger M, Schmidt-Gersbach C et al. Receptor tyrosine kinases: The main targets for new anticancer therapy. Curr Drug Targets 2003; 4: 113–21.

    Article  PubMed  CAS  Google Scholar 

  6. Thomas KA. Vascular endothelial growth factor, a potent and selective angiogenic agent. J Biol Chem 1996; 271: 603–6.

    PubMed  CAS  Google Scholar 

  7. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 13: 9–22.

    PubMed  CAS  Google Scholar 

  8. Rubanyi GM, Polokoff MA. Endothelins: Molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev 1994; 46: 325–415.

    PubMed  CAS  Google Scholar 

  9. Bagnato A, Salani D, Di Castro V et al. Expression of endothelin 1 and endothelin A receptor in ovarian carcinoma: Evidence for an autocrine role in tumor growth. Cancer Res 1999; 59: 720–7.

    PubMed  CAS  Google Scholar 

  10. Baley PA, Resink TJ, Eppenberger U, Hahn AW. Endothelin messenger RNA and receptors are differentially expressed in cultured human breast epithelial and stromal cells. J Clin Invest 1990; 85: 1320–3.

    Article  PubMed  CAS  Google Scholar 

  11. Bagnato A, Cirilli A, Salani D et al. Growth inhibition of cervix carcinoma cells in vivo by endothelin A receptor blockade. Cancer Res 2002; 62: 6381–4.

    PubMed  CAS  Google Scholar 

  12. Nelson JB, Hedican SP, George DJ et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nature Med 1995; 1: 944–9.

    Article  PubMed  CAS  Google Scholar 

  13. Takuwa Y, Masaki T, Yamashita K. The effects of the endothelin family peptides on cultured osteoblastic cells from rat calvariae. Biochem Biophys Res Commun 1990; 170: 998–1005.

    Article  PubMed  CAS  Google Scholar 

  14. Kozawa O, Kawamura H, Hatakeyama D et al. Endothelin-1 induces vascular endothelial growth factor synthesis in osteoblasts: Involvement of p38 mitogen-activated protein kinase. Cell Signal 2000; 12: 375–80.

    Article  PubMed  CAS  Google Scholar 

  15. Carducci MA, Nelson JB, Bowling MK et al. Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: Safety and pharmacokinetics. J Clin Oncol 2002; 20: 2171–80.

    Article  PubMed  CAS  Google Scholar 

  16. Bagnato A, Spinella F. Emerging role of endothelin-1 in tumor angiogenesis. Trends Endocrinol Metab 2002; 14: 44–50.

    Article  Google Scholar 

  17. Miki T, Yano S, Hanibuchi M, Sone S. Bone metastasis model with multiorgan dissemination of human small-cell lung cancer (SBC-5) cells in natural killer cell-depleted SCID mice. Oncol Res 2000; 12: 209–17.

    PubMed  CAS  Google Scholar 

  18. Corey E, Quinn JE, Bladou F et al. Establishment and characterization of osseous prostate cancer models: Intra-tibial injection of human prostate cancer cells. Prostate 2002; 52: 20–33.

    Article  PubMed  Google Scholar 

  19. Iguchi H, Yokota M, Fukutomi M et al. A possible role of VEGF in osteolytic bone metastasis of hepatocellular carcinoma. J Exp Clin Cancer Res 2002; 21: 309–13.

    PubMed  CAS  Google Scholar 

  20. Holleb AI, Folkman J. Tumor angiogenesis. CA Cancer J Clin 1972; 22: 226–9.

    PubMed  CAS  Google Scholar 

  21. Nakagawa M, Kaneda T, Arakawa T et al. Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts. FEBS Lett 2000; 473: 161–4.

    Article  PubMed  CAS  Google Scholar 

  22. Sweeney P, Karashima T, Kim S-J et al. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production. Clin Cancer Res 2002; 8: 2714–24.

    PubMed  CAS  Google Scholar 

  23. Kopetz ES, Nelson JB, Carducci MA. Endothelin-1 as a target for therapeutic intervention in prostate cancer. Invest New Drugs 2002; 20: 173–82.

    Article  PubMed  CAS  Google Scholar 

  24. Nelson JB, Nguyen SH, Wu-Wong JR et al. New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade. Urology 1999; 53: 1063–9.

    Article  PubMed  CAS  Google Scholar 

  25. Drevs J, Hofmann I, Hugenschmidt H et al. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res 60: 4819–24.

  26. Spinella F, Rosano L, Di Castro V et al. Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1 alpha in ovarian carcinoma cells. J Biol Chem 2002; 277: 27850–5.

    Article  PubMed  CAS  Google Scholar 

  27. Rai A, Gulati A. Evidence for the involvement of ET(B) receptors in ET-1-induced changes in blood flow to the rat breast tumor. Cancer Chemother Pharmacol 2003; 51: 21–8.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Tumor Biology Center at the Albert-Ludwigs-University Hospital, Freiburg, Germany

    M. Medinger, C. Schmidt-Gersbach, J. Soltau, A. Droll, C. Unger & J. Drevs

  2. Institute for Pathology, University Hospital, Freiburg, Germany

    C.P. Adler

Authors
  1. M. Medinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C.P. Adler
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Schmidt-Gersbach
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Soltau
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Droll
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C. Unger
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J. Drevs
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Medinger.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Medinger, M., Adler, C., Schmidt-Gersbach, C. et al. Angiogenesis and the ET-1/ETA Receptor System: Immunohistochemical Expression Analysis in Bone Metastases from Patients with Different Primary Tumors. Angiogenesis 6, 225–231 (2003). https://doi.org/10.1023/B:AGEN.0000021395.43438.44

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:AGEN.0000021395.43438.44

Search

Navigation